Targeted proteomics in Alzheimer’s disease: focus on amyloid-β

References

• Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet368(9533), 387–403 (2006).
   PubMed Web of Science ®Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci.12(10), 383–388 (1991).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev.81(2), 741–766 (2001).
   PubMed Web of Science ®Google Scholar
• Burdick D, Soreghan B, Kwon M et al. Assembly and aggregation properties of synthetic Alzheimer’s A4/β amyloid peptide analogs. J. Biol. Chem.267(1), 546–554 (1992).
   PubMed Web of Science ®Google Scholar
• Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry32(18), 4693–4697 (1993).
   PubMed Web of Science ®Google Scholar
• De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active γ-secretase complex. Neuron38(1), 9–12 (2003).
   PubMed Web of Science ®Google Scholar
• Sinha S, Anderson JP, Barbour R et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature402(6761), 537–540 (1999).
   PubMed Web of Science ®Google Scholar
• Vassar R, Bennett BD, Babu-Khan S et al. β-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science286(5440), 735–741 (1999).
   PubMed Web of Science ®Google Scholar
• Higgins LS, Murphy GM Jr, Forno LS, Catalano R, Cordell B. P3 β-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer’s disease brain. Am. J. Pathol.149(2), 585–596 (1996).
   PubMedGoogle Scholar
• Wei W, Norton DD, Wang X, Kusiak JW. Aβ 17–42 in Alzheimer’s disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain125(Pt 9), 2036–2043 (2002).
   PubMed Web of Science ®Google Scholar
• Koike H, Tomioka S, Sorimachi H et al. Membrane-anchored metalloprotease MDC9 has an α-secretase activity responsible for processing the amyloid precursor protein. Biochem. J.343(Pt 2), 371–375 (1999).
   PubMed Web of Science ®Google Scholar
• Nelson KK, Schlondorff J, Blobel CP. Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor α convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2β. Biochem. J.343(Pt 3), 673–680 (1999).
   PubMed Web of Science ®Google Scholar
• Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl Acad. Sci. USA98(10), 5815–5820 (2001).
   PubMed Web of Science ®Google Scholar
• Lammich S, Kojro E, Postina R et al. Constitutive and regulated α-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl Acad. Sci. USA96(7), 3922–3927 (1999).
   PubMed Web of Science ®Google Scholar
• Buxbaum JD, Liu K-N, Luo Y et al. evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem.273(43), 27765–27767 (1998).
   PubMed Web of Science ®Google Scholar
• Slack BE, Ma LK, Seah CC. Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-α converting enzyme. Biochem. J.357(Pt 3), 787–794 (2001).
   PubMed Web of Science ®Google Scholar
• Leissring MA. Proteolytic degradation of the amyloid β-protein: the forgotten side of Alzheimer’s disease. Curr. Alzheimer Res.3(5), 431–435 (2006).
   PubMedGoogle Scholar
• Waldron E, Jaeger S, Pietrzik CU. Functional role of the low-density lipoprotein receptor-related protein in Alzheimer’s disease. Neurodegener. Dis.3(4–5), 233–238 (2006).
   PubMed Web of Science ®Google Scholar
• Moir RD, Tanzi RE. LRP-mediated clearance of Aβ is inhibited by KPI-containing isoforms of APP. Curr. Alzheimer Res.2(2), 269–273 (2005).
   PubMedGoogle Scholar
• Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun.120(3), 885–890 (1984).
   PubMed Web of Science ®Google Scholar
• Masters CL, Simms G, Weinman NA et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA82(12), 4245–4249 (1985).
   PubMed Web of Science ®Google Scholar
• Shen J, Kelleher RJ III. The presenilin hypothesis of Alzheimer’s disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl Acad. Sci. USA104(2), 403–409 (2007).
   PubMed Web of Science ®Google Scholar
• Rovelet-Lecrux A, Hannequin D, Raux G et al. APP locus duplication causes autosomal dominant early-onset al.heimer disease with cerebral amyloid angiopathy. Nat. Genet.38(1), 24–26 (2006).
   PubMed Web of Science ®Google Scholar
• Neve RL, McPhie DL, Chen Y. Alzheimer’s disease: a dysfunction of the amyloid precursor protein(1). Brain Res.886(1–2), 54–66 (2000).
   PubMedGoogle Scholar
• Standridge JB. Vicious cycles within the neuropathophysiologic mechanisms of Alzheimer’s disease. Curr. Alzheimer Res.3(2), 95–108 (2006).
   PubMed Web of Science ®Google Scholar
• Stokin GB, Goldstein LS. Axonal transport and Alzheimer’s disease. Annu. Rev. Biochem.75, 607–627 (2006).
   PubMed Web of Science ®Google Scholar
• Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol.55(10), 1023–1025 (1996).
   PubMed Web of Science ®Google Scholar
• Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid-β vaccination: testing the amyloid hypothesis?: heads we win, tails you lose! Am. J. Pathol.169(3), 738–739 (2006).
   PubMedGoogle Scholar
• Rottkamp CA, Atwood CS, Joseph JA et al. The state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease. Peptides23(7), 1333–1341 (2002).
   PubMed Web of Science ®Google Scholar
• Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-β and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med.33(9), 1194–1199 (2002).
   PubMed Web of Science ®Google Scholar
• Peterson A, Lantz MS. Is it Alzheimer’s? Neuropsychological testing helps to clarify diagnostic puzzle. Geriatrics56(4), 58–61 (2001).
   PubMedGoogle Scholar
• Haass C, Schlossmacher MG, Hung AY et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature359(6393), 322–325 (1992).
   PubMed Web of Science ®Google Scholar
• Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol.38(4), 643–648 (1995).
   PubMed Web of Science ®Google Scholar
• Tabaton M, Nunzi MG, Xue R et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun.200(3), 1598–1603 (1994).
   PubMed Web of Science ®Google Scholar
• Van Nostrand WE, Wagner SL, Shankle WR et al. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc. Natl Acad. Sci. USA89(7), 2551–2555 (1992).
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Odaka A, Suzuki N et al. Visualization of A β 42(43) and A β 40 in senile plaques with end-specific A β monoclonals: evidence that an initially deposited species is A β 42(43). Neuron13(1), 45–53 (1994).
   PubMed Web of Science ®Google Scholar
• Blennow K. CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev. Mol. Diagn.5(5), 661–672 (2005).
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol.2(10), 605–613 (2003).
   PubMed Web of Science ®Google Scholar
• Bouwman FH, Schoonenboom SN, van der Flier WM et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol. Aging28(7), 1070–1074 (2007).
   PubMedGoogle Scholar
• Brys M, Pirraglia E, Rich K et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol. Aging PMID: 17889968 (2007) (Epub ahead of print).
   Google Scholar
• Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol.5(3), 228–234 (2006).
   PubMed Web of Science ®Google Scholar
• Herukka SK, Helisalmi S, Hallikainen M et al. CSF Aβ42, Tau and phosphorylated Tau, APOE ε4 allele and MCI type in progressive MCI. Neurobiol. Aging28(4), 507–514 (2007).
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neurosci. Lett.352(1), 67–69 (2003).
   PubMed Web of Science ®Google Scholar
• Skoog I, Davidsson P, Aevarsson O et al. Cerebrospinal fluid β-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement. Geriatr. Cogn. Disord.15(3), 169–176 (2003).
   PubMed Web of Science ®Google Scholar
• Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid β-amyloid 1-42 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry78(5), 461–464 (2007).
   PubMed Web of Science ®Google Scholar
• Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement. Geriatr. Cogn. Disord.24(2), 118–124 (2007).
   PubMed Web of Science ®Google Scholar
• Strozyk D, Blennow K, White LR, Launer LJ. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology60(4), 652–656 (2003).
   PubMed Web of Science ®Google Scholar
• Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol.59(3), 512–519 (2006).
   PubMed Web of Science ®Google Scholar
• Forsberg A, Engler H, Almkvist O et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging PMID: 17499392 (2007) (Epub ahead of print).
   Google Scholar
• Fagan AM, Roe CM, Xiong C et al. Cerebrospinal fluid tau/β-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol.64(3), 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Vanderstichele H, Blennow K, D’Heuvaert ND et al. Development of a specific diagnostic test for measurement of β-amyloid(1-42) in CSF. In: Progress in Alzheimer’s and Parkinson’s Diseases. Fisher A, Hanin I, Yoshida M (Eds). Plenum Press, NY, USA 773–778 (1998).
   Google Scholar
• Sergeant N, Bombois S, Ghestem A et al. Truncated β-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J. Neurochem.85(6), 1581–1591 (2003).
   PubMed Web of Science ®Google Scholar
• Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res.5(4), 1010–1016 (2006).
   PubMed Web of Science ®Google Scholar
• Vanderstichele H, De Meyer G, Andreasen N et al. Amino-truncated β-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin. Chem.51(9), 1650–1660 (2005).
   PubMed Web of Science ®Google Scholar
• Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx1(2), 226–234 (2004).
   PubMedGoogle Scholar
• Sobow T, Flirski M, Kloszewska I, Liberski PP. Plasma levels of αβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer’s disease. Acta Neurobiol. Exp. (Wars.)65(2), 117–124 (2005).
   PubMedGoogle Scholar
• Mayeux R, Honig LS, Tang MX et al. Plasma A[β]40 and A[β]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology61(9), 1185–1190 (2003).
   PubMed Web of Science ®Google Scholar
• Graff-Radford NR, Crook JE, Lucas J et al. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol.64(3), 354–362 (2007).
   PubMedGoogle Scholar
• van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Aβ(1-40) and Aβ(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol.5(8), 655–660 (2006).
   PubMed Web of Science ®Google Scholar
• Kuo YM, Emmerling MR, Lampert HC et al. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer’s disease. Biochem. Biophys. Res. Commun.257(3), 787–791 (1999).
   PubMed Web of Science ®Google Scholar
• Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett.304(1–2), 102–106 (2001).
   PubMed Web of Science ®Google Scholar
• Fukuyama R, Mizuno T, Mori S et al. Age-dependent change in the levels of Aβ40 and Aβ42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Aβ42 to Aβ40 level in cerebrospinal fluid from Alzheimer’s disease patients. Eur. Neurol.43(3), 155–160 (2000).
   PubMed Web of Science ®Google Scholar
• Kanai M, Matsubara E, Isoe K et al. Longitudinal study of cerebrospinal fluid levels of tau, A β1–40, and A β1–42(43) in Alzheimer’s disease: a study in Japan. Ann. Neurol.44(1), 17–26 (1998).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Otto M et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol. Aging25(3), 273–281 (2004).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Groemer TW et al. Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer’s disease. Biol. Psychiatry55, 524–530 (2004).
   PubMed Web of Science ®Google Scholar
• Shoji M, Matsubara E, Kanai M et al. Combination assay of CSF tau, Aβ 1-40 and Aβ 1-42(43) as a biochemical marker of Alzheimer’s disease. J. Neurol. Sci.158(2), 134–140 (1998).
   PubMed Web of Science ®Google Scholar
• Mehta PD, Pirttila T. Increased cerebrospinal fluid A β38/A β42 ratio in Alzheimer disease. Neurodegener. Dis.2(5), 242–245 (2005).
   PubMedGoogle Scholar
• Schoonenboom NS, Mulder C, Van Kamp GJ et al. Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann. Neurol.58(1), 139–142 (2005).
   PubMed Web of Science ®Google Scholar
• Hansson O, Zetterberg H, Buchhave P et al. Prediction of Alzheimer’s disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord.23(5), 316–320 (2007).
   PubMed Web of Science ®Google Scholar
• Wiltfang J, Esselmann H, Bibl M et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and in patients withzz chronic neuroinflammation. J. Neurochem.81(3), 481–496 (2002).
   PubMed Web of Science ®Google Scholar
• Höglund K, Hansson O, Buchhave P et al. Prediction of Alzheimer’s disease using a CSF pattern of C-terminally truncated β-amyloid peptides. Neurodegener. Dis. PMID: 18309230 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Bibl M, Esselmann H, Otto M et al. Cerebrospinal fluid amyloid β peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid β peptides. Electrophoresis25(17), 2912–2918 (2004).
   PubMedGoogle Scholar
• Simonsen AH, Hansson SF, Ruetschi U et al. Amyloid β1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dement. Geriatr. Cogn. Disord.23(4), 246–250 (2007).
   PubMedGoogle Scholar
• Rangachari V, Moore BD, Reed DK et al. Amyloid-β(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry46(43), 12451–12462 (2007).
   PubMedGoogle Scholar
• Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer’s disease. Biochim. Biophys. Acta1502(1), 139–144 (2000).
   PubMed Web of Science ®Google Scholar
• Bibl M, Mollenhauer B, Esselmann H et al. CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain129(Pt 5), 1177–1187 (2006).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Shankar GM et al. The role of cell-derived oligomers of Aβ in Alzheimer’s disease and avenues for therapeutic intervention. Biochem. Soc. Trans.33(Pt 5), 1087–1090 (2005).
   PubMedGoogle Scholar
• Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol.572(Pt 2), 477–492 (2006).
   PubMed Web of Science ®Google Scholar
• Lesne S, Koh MT, Kotilinek L et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature440(7082), 352–357 (2006).
   PubMed Web of Science ®Google Scholar
• Podlisny MB, Ostaszewski BL, Squazzo SL et al. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem.270(16), 9564–9570 (1995).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Townsend M, Podlisny MB et al. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J. Neurosci.25(10), 2455–2462 (2005).
   PubMed Web of Science ®Google Scholar
• Georganopoulou DG, Chang L, Nam JM et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc. Natl Acad. Sci. USA102(7), 2273–2276 (2005).
   PubMed Web of Science ®Google Scholar
• Santos AN, Torkler S, Nowak D et al. Detection of amyloid-β oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer. J. Alzheimers Dis.11(1), 117–125 (2007).
   PubMedGoogle Scholar
• Bohrmann B, Tjernberg L, Kuner P et al. Endogenous proteins controlling amyloid β-peptide polymerization. Possible implications for β-amyloid formation in the central nervous system and in peripheral tissues. J. Biol. Chem.274(23), 15990–15995 (1999).
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA90(5), 1977–1981 (1993).
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Weisgraber KH, Huang DY et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA90(17), 8098–8102 (1993).
   PubMed Web of Science ®Google Scholar
• Ghiso J, Matsubara E, Koudinov A et al. The cerebrospinal-fluid soluble form of Alzheimer’s amyloid β is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J.293 ( Pt 1), 27–30 (1993).
   PubMed Web of Science ®Google Scholar
• Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J–Alzheimer’s A β interaction. J. Biol. Chem.270(13), 7563–7567 (1995).
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Huang DY, Bhasin R, Roses AD, Goldgaber D. Avid binding of β A amyloid peptide to its own precursor. Exp. Neurol.122(2), 327–334 (1993).
   PubMedGoogle Scholar
• Deane R, Wu Z, Sagare A et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron43(3), 333–344 (2004).
   PubMed Web of Science ®Google Scholar
• Kanekiyo T, Ban T, Aritake K et al. Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid. Proc. Natl Acad. Sci. USA104(15), 6412–6417 (2007).
   PubMed Web of Science ®Google Scholar
• Portelius E, Tran AJ, Andreasson U et al. Characterization of amyloid β peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res.6(11), 4433–4439 (2007).
   PubMed Web of Science ®Google Scholar
• Ackermann BL, Berna MJ. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev. Proteomics4(2), 175–186 (2007).
   PubMed Web of Science ®Google Scholar
• Nelson RW, Krone JR, Bieber AL, Williams P. Mass spectrometric immunoassay. Anal. Chem.67(7), 1153–1158 (1995).
   PubMed Web of Science ®Google Scholar
• Hutchens TW, Yip T-T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom.7(7), 576–580 (1993).
   Web of Science ®Google Scholar
• Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of β-amyloid peptide from human cerebrospinal fluid. J. Neurochem.61(5), 1965–1968 (1993).
   PubMed Web of Science ®Google Scholar
• Davies H, Lomas L, Austen B. Profiling of amyloid β peptide variants using SELDI Protein Chip arrays. Biotechniques27(6), 1258–1261 (1999).
   PubMed Web of Science ®Google Scholar
• Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport10(8), 1699–1705 (1999).
   PubMed Web of Science ®Google Scholar
• Gelfanova V, Higgs RE, Dean RA et al. Quantitative analysis of amyloid-{β} peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief. Funct. Genomic. Proteomic.6(2), 149–158 (2007).
   PubMedGoogle Scholar
• Lewczuk P, Esselmann H, Meyer M et al. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun. Mass Spectrom.17(12), 1291–1296 (2003).
   PubMed Web of Science ®Google Scholar
• Maddalena AS, Papassotiropoulos A, Gonzalez-Agosti C et al. Cerebrospinal Fluid Profile of Amyloid β Peptides in Patients with Alzheimer’s Disease Determined by Protein Biochip Technology. Neurodegener. Dis.1(4–5 ), 231–235 (2004).
   PubMed Web of Science ®Google Scholar
• Simonsen AH, McGuire J, Podust VN et al. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer’s disease. Neurobiol. Aging PMID: 17321007 (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Portelius E, Zetterberg H, Andreasson U et al. An Alzheimer’s disease-specific β-amyloid fragment signature in cerebrospinal fluid. Neurosci. Lett.409(3), 215–219 (2006).
   PubMed Web of Science ®Google Scholar
• Andreasson U, Portelius E, Andersson ME, Blennow K, Zetterberg H. Aspects of β-amyloid as a biomarker for Alzheimer’s disease. Biomark. Med.1(1), 59–78 (2007).
   PubMed Web of Science ®Google Scholar
• Bradbury LE, LeBlanc JF, McCarthy DB. ProteinChip array-based amyloid β assays. Methods Mol. Biol.264, 245–257 (2004).
   PubMedGoogle Scholar
• Maruyama K, Kametani F, Usami M, Yamao-Harigaya W, Tanaka K. “Secretase,” Alzheimer amyloid protein precursor secreting enzyme is not sequence-specific. Biochem. Biophys. Res. Commun.179(3), 1670–1676 (1991).
   PubMed Web of Science ®Google Scholar
• Sisodia SS. β-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl Acad. Sci. USA89(13), 6075–6079 (1992).
   PubMed Web of Science ®Google Scholar
• Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1-40). J. Neurosci.16(24), 7910–7919 (1996).
   PubMed Web of Science ®Google Scholar
• Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer’s amyloid β peptide by endothelin-converting enzyme. J. Biol. Chem.276(27), 24540–24548 (2001).
   PubMed Web of Science ®Google Scholar
• Roher AE, Kasunic TC, Woods AS et al. Proteolysis of A β peptide from Alzheimer disease brain by gelatinase A. Biochem. Biophys. Res. Commun.205(3), 1755–1761 (1994).
   PubMed Web of Science ®Google Scholar
• Tucker HM, Kihiko M, Caldwell JN et al. The plasmin system is induced by and degrades amyloid-β aggregates. J. Neurosci.20(11), 3937–3946 (2000).
   PubMedGoogle Scholar
• Regnier FE, Riggs L, Zhang R et al. Comparative proteomics based on stable isotope labeling and affinity selection. J. Mass Spectrom.37(2), 133–145 (2002).
   PubMed Web of Science ®Google Scholar
• Pratt JM, Petty J, Riba-Garcia I et al. Dynamics of protein turnover, a missing dimension in proteomics. Mol. Cell Proteomics1(8), 579–591 (2002).
   PubMed Web of Science ®Google Scholar
• Gustavsson N, Greber B, Kreitler T et al. A proteomic method for the analysis of changes in protein concentrations in response to systemic perturbations using metabolic incorporation of stable isotopes and mass spectrometry. Proteomics5(14), 3563–3570 (2005).
   PubMedGoogle Scholar
• Bateman RJ, Munsell LY, Morris JC et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med.12(7), 856–861 (2006).
   PubMed Web of Science ®Google Scholar
• Mueller SG, Weiner MW, Thal LJ et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin. N. Am.15(4), 869–877, xi–xii (2005).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology69(16), 1622–1634 (2007).
   PubMed Web of Science ®Google Scholar
• Howell S, Nalbantoglu J, Crine P. Neutral endopeptidase can hydrolyze β-amyloid(1-40) but shows no effect on β-amyloid precursor protein metabolism. Peptides16(4), 647–652 (1995).
   PubMed Web of Science ®Google Scholar
• Iwata N, Tsubuki S, Takaki Y et al. Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med.6(2), 143–150 (2000).
   PubMed Web of Science ®Google Scholar
• Leissring MA, Farris W, Chang AY et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron40(6), 1087–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid β-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry38(35), 11570–11576 (1999).
   PubMedGoogle Scholar
• Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (A β); retards A β aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem.276(51), 47863–47868 (2001).
   PubMed Web of Science ®Google Scholar
• Mueller-Steiner S, Zhou Y, Arai H et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron51(6), 703–714 (2006).
   PubMed Web of Science ®Google Scholar
• Beher D, Wrigley JD, Owens AP, Shearman MS. Generation of C-terminally truncated amyloid-β peptides is dependent on gamma-secretase activity. J. Neurochem.82(3), 563–575 (2002).
   PubMed Web of Science ®Google Scholar
• Fluhrer R, Multhaup G, Schlicksupp A et al. Identification of a β-secretase activity, which truncates amyloid β-peptide after its presenilin-dependent generation. J. Biol. Chem.278(8), 5531–5538 (2003).
   PubMed Web of Science ®Google Scholar
• Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a β -secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein. Proc. Natl Acad. Sci. USA97(17), 9712–9717 (2000).
   PubMed Web of Science ®Google Scholar
• Blennow K, Nellgard B. Amyloid β 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology62(1), 159; author reply 159–160 (2004).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Hesse C, Davidsson P et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol.56(6), 673–680 (1999).
   PubMed Web of Science ®Google Scholar
• Schoonenboom NS, Mulder C, Vanderstichele H et al. Effects of processing and storage conditions on amyloid β (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem.51(1), 189–195 (2005).
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker. Neurology68(9), 666–669 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen SL. Ozone in ambient air as a source of adventitious oxidation. A mass spectrometric study. Anal. Chem.78(13), 4352–4362 (2006).
   PubMedGoogle Scholar